Initiate at OP: The Surgeon Never Sleeps; The Robot That Won't Stop Operating

Research evidence excerpt

Initiate at OP: The Surgeon Never Sleeps; The Robot That Won't Stop Operating

Key Investment Risks

Procedure volume disappointment. Any deceleration to procedure growth driven by macroeconomic

softness, hospital budget constraints, staffing shortages, or slower-than-expected adoption of robotic

techniques in general surgery would likely pressure both earnings estimates and the premium multiple

simultaneously.

GLP-1/Bariatric headwind accelerates beyond expectations. The ongoing decline in bariatric surgery

volumes driven by GLP-1 adoption represents a known and growing headwind to U.S. procedure growth.

Any acceleration in bariatric volume deterioration beyond current assumptions, or any evidence that

GLP-1 adoption is beginning to impact adjacent procedure categories, would negatively impact U.S.

procedure growth estimates.

Competitive pressure intensifies. The robotic surgery landscape is becoming increasingly contested.

Medtronic's Hugo RAS system received FDA clearance for urologic procedures in December 2025 and is

actively pursuing gynecologic and hernia indications. Johnson & Johnson's OTTAVA system has submitted

for FDA De Novo classification and CMR Surgical's Versius platform is gaining traction internationally.

Any evidence of meaningful market share loss, pricing pressure on capital equipment, or acceleration in

instrument remanufacturing adoption could challenge ISRG's recurring revenue model.

China deterioration. China represents a meaningful long-term growth opportunity, but near-term

dynamics are challenging. Low tender activity, provincial preferences for domestic suppliers, intense

price competition from local robotic manufacturers, and stringent pricing caps on robotic procedure

reimbursement have already compressed win ratios.